Announced Date: 2025-01-13 (January 13, 2025)
Asset Name: SIM0500
Licensor: Simcere Zaiming (a subsidiary of Simcere Pharmaceutical Group Ltd，China)
Licensee (Buyer): AbbVie Inc.（US）
.
Asset Modality: TsAbs (humanized trispecific antibody)
Asset Target: GPRC5D, BCMA, and CD3,
Potential Indication: Multiple Myeloma
Current Stage: Phase 1 , in both China and the U.S.
Scope of Authority: Co-development, an option to license
.
Deal Detail:
Upfront payment and milestone payments up to $1.055 billion,
Tiered royalties on net sales outside of the Greater China territory.
.
Link:
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
